WASHINGTON, Jan. 7 /PRNewswire-USNewswire/ -- Nanotechnology was incorporated into more than $60 billion in manufactured goods last year. By 2014, the market will grow to $2.6 trillion. By 2011, over $15 billion in nano-enabled drugs and therapeutics will be sold--up from more than $3 billion in 2006. And industry experts project that nanotechnology will be incorporated into $20 billion worth of consumer food products by 2010.
Advertisement
With this rapid commercialization -- and with a new Administration in power - all eyes are on federal government regulators to find out how they intend to deal with this burgeoning issue. FDLI, in partnership with Burdock Group and Arizona State University ahs assembled -- in one forum -- top officials at the agencies responsible for the regulation of nanotechnology products -- including the Food and Drug Administration and the Environmental Protection Agency to discuss their plans for managing and monitoring these products.
Advertisement
FDA speakers include: Norris Alderson, FDA Nanotechnology Task Force; John Weimer, Office of Chief Counsel; Subhas Malghan, Center for Devices and Radiological Health; Linda Katz, Center for Food Safety and Applied Nutrition; Mitchell Cheeseman, Center for Food Safety and Applied Nutrition; and Douglas Throckmorton, Center for Drug Evaluation and Research.
Jessica Barkas, Program Attorney in the Chemical Control Division of the Environmental Protection Agency, also will be speaking at the meeting.
At FDLI's 2nd Annual Conference on Nanotechnology Law, Regulation and Policy, February 18-199, 2009, at the L'Enfant Plaza Hotel, in Washington, D.C., food and drug industry representatives also will find out what's happening internationally on nanotech regulation, how venture capitalists look at the future of nanotechnology and what the leading corporations, scientific laboratories and academic centers are focusing on in this dynamic field.
This groundbreaking conference will seek answers to these questions:
> What progress is FDA making in implementing its Nanotechnology Task Force Report?
> What can FDA learn from EPA and other oversight agencies in NNI?
> Will the heavily Democratic Congress invest in and/or regulate more than under the Bush Administration?
> Are workers exposed to asbestos-like dangers from dealing with nano products?
> How does a responsible company devise a risk management plan for nanotech development -- one that takes into account OSHA and NIOSH policy?
> What is reasonable and required federal funding for U.S nanotechnology R&D, including monies for safety and social policy research?
> Are China and Japan ahead of the U.S. in nanotech development?
> For nanotech products and processes, should particle size make a regulatory difference?
Other featured speakers and moderators include:
Scott Livingston, Capital Management/The Livingston Group
Andrew Maynard, Woodrow Wilson International Center for Scholars
George Burdock, Burdock Group
Tie Lan, NanoCor Inc.
Robert J. Nicolosi, University of Massachusetts, Lowell
Ralph Hall, University of Minnesota Law School
Matthew Jaffe, Crowell & Moring, LLP
Les Makepeace, Colorado Nanotechnology Alliance
Sean Murdock, NanoBusiness Alliance
Jay Ansell, Personal Care Products Council
James Chen, Crowell & Moring, LLP
John Howard, Public Health Law Program, Centers for Disease Control
Jim O'Reilly, Baker & Daniels
Jessica Barkas, Environmental Protection Agency
Henry Chajet, Patton Boggs
Rachel Lattimore, Arent Fox
John Monica, Porter Wright
Susan Brienza, Patton Boggs
Lynn L. Bergeson, Bergeson & Campbell, P.C.
Don Ewert, Oso BioPharmaceuticals
Michael J. Kosnett, University of Colorado, Denver and Colorado School of Public Health
Erli Chen, Nanotechnology Commercialization Group, NTI
Gary Marchant, Arizona State University
Diana Bowman, Monash University
Steffi Friedrichs, Nanotechnology Industries Association
John Pendergrass, Environmental Law Institute
David Guston, Center for Nanotechnology in Society
Jordan Paradise, University of Minnesota Law School
Vickie Sutton, Texas Tech University School of Law
Burdock Group has more than 20 years of expertise regarding ingredient safety and regulatory consultation services. Burdock Group's team offers mission-critical services that include Generally Recognized as Safe (GRAS), New Dietary Ingredient Notifications (NDINs), Consumption Analysis, Claims substantiation, Toxicology and Risk Assessment, Literature Searches and Label Reviews. For more information, visit www.BurdockGroup.com.
The Center for the Study of Law, Science & Technology at Arizona State University is the nation's oldest and largest academic center focusing on the intersection of law with science and technology, and is currently engaged in a three-year study funded by the DOE on regulation of nanotechnology.
To register for the conference, visit www.fdli.org or call (800) 956-6293 or (202) 371-1420.
Founded in 1949, FDLI publishes the award-winning, peer-reviewed Food and Drug Law Journal; the bimonthly magazine Update; FDA Directory; and dozens of books and publications for attorneys, regulatory affairs practitioners, scientists, health care professionals, government employees and marketers in the food and drug field. For more information, visit www.fdli.org
SOURCE Food and Drug Law Institute
